Teva Pharmaceutical Industries Limited
TEVA
$26.88
$0.160.60%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 712.00M | -158.00M | -1.29B | -1.64B | -959.00M |
| Total Depreciation and Amortization | 1.01B | 1.02B | 1.03B | 1.06B | 1.06B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.18B | 1.49B | 2.16B | 2.26B | 1.66B |
| Change in Net Operating Assets | -1.84B | -964.00M | -638.00M | -435.00M | 102.00M |
| Cash from Operations | 1.07B | 1.39B | 1.27B | 1.25B | 1.86B |
| Capital Expenditure | -488.00M | -500.00M | -501.00M | -498.00M | -488.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 0.00 | -15.00M | -15.00M |
| Divestitures | 38.00M | 68.00M | 60.00M | 43.00M | 39.00M |
| Other Investing Activities | 1.22B | 1.34B | 1.29B | 1.26B | 1.36B |
| Cash from Investing | 774.00M | 907.00M | 849.00M | 792.00M | 891.00M |
| Total Debt Issued | 2.31B | 2.31B | -- | -- | 0.00 |
| Total Debt Repaid | -4.80B | -4.35B | -3.01B | -1.64B | -1.46B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -366.00M | -364.00M | -375.00M | -150.00M | -237.00M |
| Cash from Financing | -2.87B | -2.41B | -3.38B | -1.79B | -1.69B |
| Foreign Exchange rate Adjustments | -90.00M | 19.00M | -25.00M | -174.00M | 15.00M |
| Miscellaneous Cash Flow Adjustments | -1.00M | -1.00M | 0.00 | -1.00M | 0.00 |
| Net Change in Cash | -1.12B | -97.00M | -1.29B | 73.00M | 1.07B |